CRISPR-dCas9 powered impedimetric biosensor for label-free detection of circulating tumor DNAs

Anal Chim Acta. 2020 Jul 18:1121:35-41. doi: 10.1016/j.aca.2020.04.009. Epub 2020 Apr 16.

Abstract

Label-free biosensors which can be integrated into lab-on-a-chip platforms have the advantage of using small volumes for rapid and inexpensive measurements contrary to label-based technologies which are often more costly and time-consuming. In this study, graphene oxide screen printed electrodes (GPHOXE) were modified by deactivated Cas9 (dCas9) proteins and synthetic guide RNA (sgRNA) as the biorecognition receptor for label-free detection of circulating tumor DNAs (ctDNA). This was achieved by detection of a tumor related mutation (PIK3CA exon 9 mutation) via sequence-specific recognition followed by electrochemical impedance spectroscopy (EIS) analysis. The biosensor showed high specificity as there was no impedance signal for other ctDNA sequences, even the single nucleotide mismatch. dCas9-sgRNA modified biosensor demonstrated linear detection limits between 2 and 20 nM for 120 bp ctDNA's in 40 s. The calibration curve showed good linearity, LOD was calculated as 0.65 nM and LOQ was calculated as 1.92 nM. Selectivity and repeatability studies were carried out in real blood samples and the recovery was higher than 96%. In conclusion, dCas9-sgRNA was effectively immobilized and optimized on GPHOXE as the selective biorecognition receptor of this ultrafast impedimetric biosensor. The CRISPR-dCas9 powered impedimetric system showed good selectivity, high repeatability and good recovery properties. This is the first literature to report the use of CRISPR/Cas technology as a label-free tool that can be used in an impedimetric system for detection of ctDNA's.

Keywords: CRISPR/Cas9 technology; Cancer diagnosis; Chronoimpedance; Circulating tumor DNA; Deactivated Cas9; Electrochemical impedance spectroscopy; Impedimetric biosensor; Label-free analysis; Liquid biopsy.

MeSH terms

  • Biosensing Techniques / methods*
  • CRISPR-Cas Systems / genetics*
  • Circulating Tumor DNA / blood*
  • Class I Phosphatidylinositol 3-Kinases / genetics
  • Dielectric Spectroscopy
  • Electrodes
  • Graphite / chemistry
  • Humans
  • Limit of Detection
  • RNA, Guide, CRISPR-Cas Systems / metabolism
  • Reproducibility of Results

Substances

  • Circulating Tumor DNA
  • RNA, Guide, CRISPR-Cas Systems
  • graphene oxide
  • Graphite
  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CA protein, human